Fig. 6

Knockdown PPP2R1A sensitizes cancer cells to nelfinavir treatment. A Expression of PPP2R1A in normal lung epithelial cells (BEAS-2B) and lung adenocarcinoma cells (A549, PC9, SPCA1 and H1299). B, C Protein (B) and mRNA (C) level of PPP2R1A were determined in PC9 knockdown PPP2R1A cell lines. D, E Protein (D) and mRNA (E) level of PPP2R1A were determined in A549 overexpressing PPP2R1A cell lines. F CCK8 assay measured the cell viability of A549 overexpressing PPP2R1A cell lines under the treatment of nelfinavir (20 μmol), cisplatin (20 μmol) or velnacrine (200 μmol) for 24 h. G CCK8 assay measured the cell viability of PC9 knockdown PPP2R1A cell lines under the treatment of nelfinavir (20 μmol), cisplatin (20 μmol) or velnacrine (200 μmol) for 24 h. H PC9 knockdown PPP2R1A cell lines under the treatment of nelfinavir (10 μmol) for 24 h. Apoptosis was detected by Annexin V-FITC/PI staining. I Percentages of early-stage and late-stage apoptotic cells among the three groups. J LDH release of PC9 knockdown PPP2R1A cell lines under the treatment of nelfinavir (10 μmol, 20 μmol) for 24 h. K Western blot detected apoptosis and pyroptosis-related protein in knockdown PPP2R1A cell lines